IPSEY News and Press, Ipsen SA ADR From 06/14/23

2023-06-14 13:32:05 ET The FDA’s decision to expand the label for liver disease therapy Bylvay from French pharma Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) pressured the U.S. biotech Mirum Pharma ( NASDAQ: MIRM ) – which markets a rival therapy – on Wednesda...

NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on May 16 th and 17 th are now...

2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday May16 and Wednesday, May17, featuring live webcast presentations from international companies with American Depositary Rec...

2023-04-24 03:10:30 ET Global specialty-driven biopharmaceutical company, Ipsen ( OTCPK:IPSEY ) appoints of Sandra Silvestri, M.D., Ph.D., as EVP, CMO and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023. She will serve on the ...

2023-04-19 11:56:38 ET Summary The addition of Bylvay to its portfolio is expected to have a positive impact on the company's medium-term growth prospects. The threat of competition from Livmarli could curb Bylvay's potential. The looming patent expiry of Onivyde/Cabometyx in ...

2023-03-16 17:44:59 ET The US FDA has set August 16 as the new action date for Ipsen's ( OTCPK:IPSEY ) resubmitted New Drug Application for palovarotene for fibrodysplasia ossificans progressiva. In December 2022, the French pharma received a Complete Response Lette...

2023-03-09 09:05:52 ET Exelixis ( NASDAQ: EXEL ) shares ticked higher in the pre-market trading Thursday after Wells Fargo launched its coverage on the cancer drugmaker with an Overweight recommendation and a $23 per share target citing the sales potential of its lead rev...

Ipsen S.A. (IPSEY) Q4 2022 Results Conference Call February 09, 2023 07:45 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - CFO Howard Mayer - Head, Research and Development Conference Call Participants Elizabeth Walton - Credit Suisse ...

Ipsen S.A. press release ( OTCPK:IPSEY ): FY Non-GAAP EPS of €10.51. Revenue of €3.02B (+14.4% Y/Y). 2022 core operating margin of 36.9%, broadly in line with 2021. 2023 financial guidance : total-sales growth greater than 4.0% at CER1 ; core operat...